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mesenchymal brain neoplasm and nevus of a
child with neurocutaneous melanosis
Francis Shih1, Stephen Yip2, Patrick J McDonald3, Albert E Chudley4 and Marc R Del Bigio5*Abstract
A 28-month female with a clinical diagnosis of neurocutaneous melanosis and numerous intracranial abnormalities
(including a right choroid plexus tumor and left hemimegalencephaly) presented with a rapidly expanding tumor
in the left occipital cerebrum. Microscopic examination of the resected specimen revealed a myxoid mesenchymal
neoplasm consisting of fusiform cells that were immunoreactive for vimentin, CD34, and P53 but no melanocyte
markers. Focused amplicon deep sequencing on DNA extracted from the brain tumor and a cutaneous nevus
revealed a heterozygous (c.37G > C; p.G13R) substitution in the NRAS gene. DNA sequencing of “normal” skin and
buccal swab showed the identical NRAS change albeit at lower allelic frequency. Her parents did not harbor the
NRAS mutation. The skin lesion, but not the brain tumor, had a BRAF mutation (c.1397G > T; p.G466V). A germline
single nucleotide polymorphism in MET was found in the child and her father (c.3209C > T; p.T1010I). The findings
suggest NRAS mosaicism that occurred sometime after conception and imply an oncogenic role of the activating
NRAS mutation in both the brain and skin lesions in this child.
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Neurocutaneous melanosis (NCMS; Mendelian Inherit-
ance in Man MIM# 249400) is a rare congenital phako-
matosis consisting of numerous giant cutaneous nevi
along with extensive leptomeningeal melanosis. Approxi-
mately 100 cases have been described in the literature
[1]. The pathogenesis of NCMS likely involves a mor-
phogenetic error in which melanocyte precursors derived
from the neural crest migrate abnormally and proliferate
locally [2,3]. Most cases with an identifiable cause have a
somatic gain-of-function mutation in codon 61 of the
NRAS gene (MIM# 164790) located on chromosome 1p13
[4-7]. Approximately 30% of affected children have mel-
anin deposits detectable in the leptomeninges or brain [8]
and half have epilepsy [9].
We present a case of a female infant with NCMS who
developed an unusual myxoid mesenchymal brain tumor.* Correspondence: Marc.Delbigio@med.umanitoba.ca
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of NRAS in the melanocytic nevi and the brain tumor.Case report
Clinical details
This female child was born to a healthy non-consan-
guineous couple after an uneventful full-term pregnancy.
At birth she had numerous slightly raised, hairy melano-
cytic lesions on the scalp, neck, upper trunk, upper ex-
tremities, and hands; the largest was 4–5 cm in greatest
dimension (Figure 1). Skin lesions from the neck, scalp,
and arm were previously excised and diagnosed as in-
tradermal and compound nevi with congenital features.
She had normal height but was macrocephalic (97th per-
centile head circumference). She had been admitted to
hospital numerous times for uncontrolled seizures start-
ing at age 2 months. Magnetic resonance (MR) imaging
of the brain and spine was performed at 3.5 months age.
T1 weighted images showed a solitary 2 mm focus of in-
creased signal intensity in the right cerebellopontine cis-
tern; this was thought to represent melanin deposition.
Cystic lesions, the largest of which was 2.7 cm diameter,d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Photograph of the patient at 14 months age showing
giant congenital melanocytic nevi on each shoulder and
numerous smaller satellite nevi on the neck, scalp, arms, and
upper trunk.
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fluid (CSF) were present around the atria of the lateral
ventricles in the right cerebellopontine cistern along
with small cysts around the bodies of the lateral ventri-
cles. The left cerebral hemisphere was larger than the
right, and parietal white matter volume was abnormally
small. The combination of giant congenital nevi along
with cerebral melanin deposition led to a clinical diagno-
sis of NCMS [10]. A CT scan of the head performed at
4 months age during an episode of status epilepticus
showed no additional abnormalities. An abdominal so-
nogram performed the following day showed no ab-
normalities. Repeat MR imaging showed the presumed
melanocytic nodule had increased to 3 mm; it was hy-
perintense on T1, hypointense on T2, and hyperintenseon FLAIR. The periventricular cysts had increased in
size and quantity. A new lesion in continuity with the
choroid plexus was expanding the temporal horn of the
right lateral ventricle. MR imaging of the brain at 21
months age showed a new left occipital brain tumor that
was T2 hyperintense and enhanced strongly following
administration of gadolinium-DTPA. It grew from 1.6 ×
1.5 × 1.2 cm to 4.0 × 3.6 × 3.2 cm 4 months later
(Figure 2). A left occipital craniotomy was performed
at 24.5 months age. The tumor was not in contact with
the meninges. It had a single vascular pedicle. There
was an easily identified plane between it and the adja-
cent brain. The tumor was removed in one piece with-
out complication. MR imaging of the brain 26 months
after surgery (51 months age) showed no recurrence of
the tumor; a vague region of non-enhancing T2 signal
abnormality in the right medial occipital lobe had ex-
panded slightly.
Histopathological characterization
The tumor was a 4.5 × 3.5 × 3 cm firm tan nodule
with a smooth external surface and uniform cut surface
(Figure 3A). The brain tumor and skin biopsies were
fixed in 10% neutral buffered formalin, dehydrated and
embedded in paraffin wax for sectioning (5 uM in thick-
ness). All samples were stained with hematoxylin and
eosin for histologic evaluation. Immunohistochemistry
was performed using primary antibodies against vimentin
(mouse monoclonal, V9, Dako), CD34 (mouse monoclo-
nal, QBEND-10, Dako), alpha B crystallin (mouse mo-
noclonal, G2JF, Novocastra), CD56 (mouse monoclonal,
CD564, Dako), D240 (mouse monoclonal, D2-40, Dako),
CD99 (mouse monoclonal, 12E71, Dako), Bcl2 (mouse
monoclonal, 124, Dako), p53 (mouse monoclonal, D0-7,
Dako), Ki67 (mouse monoclonal, MIB-1, Dako), HLA-DR
(mouse monoclonal, CR3/43, Dako), Factor 13a (mouse
monoclonal, EP3372, Cellmarque), GFAP (rabbit poly-
clonal, Dako), S100 (rabbit polyclonal, Dako), Collagen
IV (mouse monoclonal, C1V22, Dako), pan-cytokeratin
(mouse monoclonal, AE1/AE3, Dako), EMA (mouse mo-
noclonal, E29, Dako), CD57 (mouse monoclonal, TB01,
Dako), HMB-45 (mouse monoclonal, HMB45, Dako),
MART-1/Melan-A (mouse monoclonal, A103, Dako), cal-
retinin (rabbit polyclonal, Cellmarque), neurofilament
(mouse monoclonal, 2 F11, Dako), synaptophysin (mouse
monoclonal, 27G12, Novocastra), NeuN (mouse mono-
clonal, A60, Lifespan Biosciences). Antigen retrieval was
performed in a Bull’s Eye Decloaking chamber (Biocare
Medical, Concord, CA) for 1 minute at 125°C utilizing a
Dako pH9 retrieval solution. All antibodies were detected
using the Dako Envision system (Dako) and diamino-
benzidine precipitation solution. A sample of the tumor
was fixed in 2.5% buffered glutaraldehyde, post-fixed
in osmium tetroxide, dehydrated in graded ethanol, and
Figure 2 Magnetic resonance image of the brain. At 14 months
age (upper image, coronal, T2 weighted) an enlarged left temporal
lobe and a tumor of the right choroid plexus (arrow) were apparent.
At 23 months age (lower image, horizontal, T1-weighted) a 4 cm
tumor is present in the left occipital lobe. Periventricular cysts are
located adjacent to the right occipital horn (arrow).
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stained with toluidine blue, and ultrathin sections were
contrasted with uranyl acetate and lead citrate then viewed
with electron microscopy using a JEM 1010 transmission
electron microscope (JEOL Ltd., Tokyo, Japan).Microscopic examination showed an indistinct inter-
face with the brain parenchyma. The tumor had a diffuse
pattern of stellate and elongated cells with delicate
processes in a loose myxoid background. There were no
pigmented cells. Numerous small, multinucleated cells
were evenly distributed within the lesion (Figure 3B).
Rarely the cells clustered around blood vessels. Very rare
mitotic figures were present and there was no necrosis
or endothelial hyperplasia. Focal areas of the extracellu-
lar material stained with Alcian blue (Figure 3C). Reticu-
lin staining was negligible. By immunohistochemistry,
the cells were positive for vimentin, CD34 (Figure 3D),
CD56, D240, Bcl2, CD99 (weak), and P53. A subpopula-
tion of cells was Factor 13a positive. An estimated 5-10%
of nuclei were Ki67 positive. Only perivascular cells
(likely astrocytes) were positive for glial fibrillary acidic
protein (GFAP), S100, and alpha B crystallin. Blood ves-
sel walls were positive for E cadherin and collagen IV.
There was no immunoreactivity for cytokeratin (AE1/3),
epithelial membrane antigen (EMA), CD57, HMB-45,
MART-1/Melan-A, calretinin, neurofilament, synaptophy-
sin, or NeuN. Scattered HLA-DR positive cells were likely
infiltrating microglia. Electron microscopic examination
showed fusiform cells with abundant rough endoplasmic
reticulum and prominent intermediate filaments but
no specific secretory organelles or obvious inter-
cellular junctions. The cells lacked a well-defined base-
ment membrane and were surrounded by a flocculent
extracellular material with rare clusters of striated collagen
bundles (Figure 3E, 3F). The diagnostic categorization
arrived at locally and supported by external consultation
was myxoid mesenchymal brain tumor of uncertain
growth potential.
DNA extraction and sequencing
Genomic DNA was extracted from formalin-fixed paraffin-
embedded samples of the intracranial tumor, an excised
cutaneous nevus lesion, and grossly unaffected skin. DNA
was also extracted from swabbed buccal cells of the
patient and both of her parents. DNA was quantitated
using the Qubit 2.0 fluorometer (Life Technology). Fo-
cused deep sequencing of 10 ng of genomic DNA ex-
tracted from the above samples was performed using the
Ion AmpliSeq Cancer panel (Life Technology). This in-
cludes PCR primers covering 739 potential cancer-related
hotspot mutations in 46 genes including KRAS, NRAS,
BRAF, PIK3CA, and IDH1 [11]. This technology permits
the interrogation of genetic alterations including mu-
tations and insertions/deletions, even minor alleles in
complex samples, in suboptimal specimens including
formalin-fixed paraffin-embedded tissues. Processing of all
samples was performed according to the manufacturer’s
protocol. Construction and enrichment of the emulsion
PCR library was performed using the Ion OneTouch
Figure 3 Macroscopic and microscopic appearance of the tumor. (A) The firm tumor was easily dissected from the surrounding brain tissue
and had a smooth tan-yellow glistening cut surface. (B) Microscopic examination revealed a paucicellular tumor consisting of predominantly
fusiform cells in a myxoid background. There is moderate nuclear pleomorphism with a multinucleated cell in the center (hematoxylin & eosin).
(C) The loose myxoid background stained positive for Alcian blue. (D) Immunohistochemical staining for CD34 is diffusely positive. (E) Electron
microscopic examination showed stellate cells with long delicate processes and occasional multinucleation. (F) The extracellular material is
abundant with clusters of collagen fibers. (Original magnifications: B-C, ×400; D, ×200; E, ×2000; F ×30000).
Table 1 Allelic frequency of nucleotide change in NRAS
and BRAF from deep amplicon sequencing of pathology
specimens and buccal swabs
Gene NRAS BRAF
Chromosome position (hg19) 1:115258745 7:140481411
Nucleotide change c.37G > C c.1397G > T
Amino acid change p. Gly13Arg p. Gly466Val
Allelic frequencies (%)
Mesenchymal brain tumor 58.0 0.0
Melanocytic nevus 33.0 32.0
Normal skin 4.8 0.0
Buccal swab 2.7 0.0
Mother buccal swab 0.0 0.0
Father buccal swab 0.0 0.0
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316 sequencing chips using the Ion Torrent Personal
Genome Machine (Life Technology) following the manu-
facturer’s protocol. Data analysis including alignment to
hg19 human reference genome, base calling, and identifi-
cation of variants was done using the Ion Variant Caller
(version 2.2). Somatic variants from the brain tumor and
the melanocytic nevus were identified after filtering out
germline changes identified from the patient’s buccal
swab. Allele frequency of a variant is calculated by dividing
the number of variant reads by total reads in the same
nucleotide position. All variants are covered by a mini-
mum of 500 reads.
The panel identified a missense mutation (chr1:1152
58745; c.37G > C) in NRAS that results in a p. G13R
amino acid substitution. The allelic frequency of the nu-
cleotide change in the brain tumor and the cutaneous
nevus (58% and 33% respectively) is consistent with a
heterozygous mutation (Table 1). The same change was
observed at an allelic frequency of 4.8% in the normal
skin and 2.7% in the buccal swab of the patient. Deep
sequencing of DNA extracted from the buccal swabs from
both parents did not reveal NRAS mutations. A BRAF
somatic nucleotide change (chr7: 140481441; c.1397G > T)
resulting in amino acid substitution p. G466V was de-
tected only in the nevus at an allelic frequency of 32%. A
single nucleotide polymorphism (SNP) resulting in a mis-
sense mutation (chr7: 116411990; c. 3209C > T; p.T1010I;)was found in the MET gene of the child’s tumor and
buccal swab as well as in the buccal swab of the father.
Discussion and conclusions
Neurocutaneous melanosis (NCMS), first described by
Rokitansky in 1861 [12], is a rare congenital disorder
consisting of multiple large melanocytic cutaneous nevi
and melanocytic proliferations in the leptomeninges [13].
Malformative lesions of the posterior fossa have rarely
been described [14,15]. Recent genetic findings have clari-
fied the pathogenesis of NCMS and large/giant congenital
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NRAS codon 61 and associated mosaicism are responsible
for the majority of NCMS cases [5] and large/giant con-
genital melanocytic nevi [17]. The same mutation is com-
mon in congenital melanocytic nevi [18]. The NRAS p.
G13R somatic mosaicism in this patient is unusual and, to
our knowledge, is the first instance reported in association
with NCMS. The presence mosaicism in combination
with the absence of mutation in the parents suggests this
mutation likely occurred after conception. This is consist-
ent with the mosaicism hypotheses for NCMS and other
phakomatoses [19]. This child does not show any dys-
morphic features associated with germline mutations
in NRAS, which are usually similar to Noonan syndrome
[20]. NRAS mutations are considered important in the
genesis of melanoma. NRAS activates four major signaling
pathways including RAF-MEK-ERK, RalGDS, PI3K-AKT/
PDK1, and PLC/PKC [21]. Mutations affecting codons 12,
13 and 61, lead to constitutive activation of RAS GTPase
in the absence of growth factor signaling and ultimately
neoplastic growth. The specific NRAS G13R mutation
identified in this case has been rarely found in melanomas
of the skin [22-24] and esophagus [25] as well as in 1/27
patients with large congenital melanocytic nevi [26,27]. In
melanoma the most common NRAS (Q61R, Q61L, Q61K)
and BRAF (V600E, V600K) mutation sites and substitu-
tions differ from those found in this patient [28].
In addition to NCMS, this child had a low-grade mes-
enchymal brain tumor, which itself is very rare. Typically
children with NCMS do not develop sarcomas, although
one rhabdomyosarcoma was described in a congenital
giant nevus [29]. Children with NCMS are reported to
develop choroid plexus papilloma and meningioma [5].
Primary sarcomas of the brain represented only 0.36% of
brain tumors in one very large series [30] and 0.7% of all
sarcomas in another series [31]. Most likely arise from
the meninges or blood vessels; among them are rhabdo-
myosarcoma, fibrosarcoma, leiomyosarcoma, and angio-
sarcoma. Primary non-meningeal myxoid mesenchymal
intracranial tumors are especially rare. Reported cases
include two low-grade fibromyxoid sarcomas [32,33] and
one myxofibrosarcoma, the diagnosis of which was based
on fluorescent in situ hybridization (FISH) analysis of the
FUS/CREB3L2 translocation [34]. Both of these tumors
have some features similar to the reported child’s brain
tumor. It is important to emphasize that the tumor had
no morphologic or immunophenotypic features of me-
lanoma. The relatively low-grade appearance of the
brain tumor presented herein is discrepant with its
rapid growth. The rapid increase in size could be
explained by expansion of the myxoid extracellular
material rather than neoplastic cell proliferation.
The heterozygous state of NRAS in the melanocytic ne-
vus and the brain tumor combined with additional novelsomatic mutations suggest cooperative involvement of
oncogenic pathways in the brain tumor and especially in
the skin lesions (BRAF p.G466V). Only a single sarcoma (a
rhabdomyosarcoma) has been described with the NRAS p.
G13R mutation [35]. Somatic mosaics of NRAS mutations
in almost identical protein regions (G12D, G12S, G13D)
have been described in relation to juvenile myelomonocytic
leukemia [36,37]. Note that neurofibromin is a major regu-
lator of the NRAS pathway [38]. NF1 is not assessed in the
AmpliSeq Cancer Panel and we did not attempt direct se-
quencing. However, given that the documented abnormal-
ities are distal to neurofibromin signaling, a mutation in
NF1 is not necessary to explain this child’s phenotype.
A germline SNP was found in the MET gene of this
child (inherited from her father who is not known to have
any neoplastic disease). The MET gene encodes the recep-
tor for hepatic growth factor/scatter factor (HGF/SF) and
appears to be involved in cell motility, proliferation, and
invasiveness [39]. Mice that overexpress HGF/SF over-
stimulate the MET pathway and develop melanosis in the
central nervous system and patterned hyperpigmentation
of the skin similar to NCMS [40]. These mice also develop
fibrosarcoma and rhabdomyosarcoma [41]. MET has been
detected by immunohistochemistry in optic canal nevus
cells from a child with NCMS [42]. The p.T1010I variant
has been identified in thyroid carcinomas [33], neuroen-
docrine carcinoma (NEC) of lung [43], a pleomorphic
xanthoastrocytoma case [11], and has been implicated as a
risk factor for familial colorectal cancer [44]. One early re-
port described this change in MET as capable of altering
signaling in NEC [45], however more recently this vari-
ation was not shown to alter c-Met phosphorylation in
NEC [46], nor does it seem capable of transforming the
Ba/F3 pro-B lymphocyte cell line [47]. To summarize, the
significance of theMET SNP in this child is unclear.
Hemimegalencephaly has been associated with other
neurocutaneous syndromes including epidermal nevus
syndrome, proteus syndrome, hypomelanosis of Ito, and
neurofibromatosis-1 [48,49]. Recently, de novo somatic
mutations with mosaicism in the PI3K-AKT3-mTOR
pathway were shown to cause hemimegalencephaly [50].
NRAS is known to have direct interaction with PI3K
[21]. Given that this child had no mutation in PI3K,
the NRAS mosaicism is likely the explanation for the
hemimegalencephaly.
Conclusion
In summary, development of a primary intracerebral
mesenchymal neoplasm in a child with NCMS and he-
mimegalencephaly can likely be explained by specific
NRAS mutant mosaicism possibly in combination with
a MET germline variation, which together constitute a
unique combination. This case highlights the importance
of DNA analysis from multiple sites, as well as from
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presence of an NRAS somatic mosaic supports the hy-
pothesized developmental pathogenesis of NCMS. Further
exploration of the role of NRAS and MET in develop-
ment of the neural crest derived pigment cells will be
of interest.
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